China will cut to 3 percent the value-added tax on the imports and the domestic production and circulation of more anti-cancer and rare-disease drugs.Starting on Dec. 1, a total of 71 such drugs and active pharmaceutical ingredients will benefit from the tax reduction, according to a statement jointly issued by the Ministry of Finance and other government agencies.The move seeks to lower costs for patients and boost China's pharmaceutical industry.This is the third batch of anti-cancer and rare-disease drugs and active pharmaceutical ingredients to benefit from such a policy since 2018.China will cut to 3 percent the value-added tax on the imports and the domestic production and circulation of more anti-cancer and rare-disease drugs.Starting on Dec. 1, a total of 71 such drugs and active pharmaceutical ingredients will benefit from the tax reduction, according to a statement jointly issued by the Ministry of Finance and other government agencies.The move seeks to lower costs for patients and boost China's pharmaceutical industry.This is the third batch of anti-cancer and rare-disease drugs and active pharmaceutical ingredients to benefit from such a policy since 2018.
